The initial public offering of Orzax, managed through a consolidated framework of capital increases and shares via secondary market distributions, has concluded. Managed under the leadership of İnfo Yatırım, the listing reached its formal conclusion during a Bell Ceremony held at Borsa Istanbul on Tuesday, July 7, positioning the equity squarely within the high-liquidity Stars Market segment.
The bookbuilding sequence previously generated a final IPO volume of 3,622,500,000 TRY, matching the asset metrics of nearly 1 million retail and corporate accounts. Positioned as a prominent primary market placement, the transaction represents a significant milestone for equity distribution frameworks and capital market depth metrics across the domestic exchange.
Corporate Strategy and Capital Allocation Layouts
Commenting on the mechanism of utilizing public listings as an institutional vehicle for corporate finance and capacity scalability, Borsa Istanbul CEO Korkmaz Ergun remarked:
Orzax was established with a successful entrepreneurial spirit and has become a strong brand today. It continues its growth through its R&D center, diversifying its product portfolio, expanding its market network, and exporting. Today, by starting to trade on our Exchange, it will realize its investments with the financing provided from the IPO, increase its production capacity, and thus walk firmly towards its growth targets. I wish the IPO to be beneficial to our capital markets and say welcome to ORZAX to our Exchange family.
Reviewing consortium logistics and the long-term impacts of public floating programs on market depth indices, İnfo Yatırım Deputy General Manager Hüseyin Güler added:
We are delighted to successfully complete the IPO of Orzax, which is a token of approximately 3 years of hard work where we assumed the consortium leadership, and to be together at the bell ceremony. The intense interest shown by approximately 1 million investors clearly demonstrates both the strong potential of the company and the confidence felt in our capital markets. With 29 IPOs we have realized in the last 5 years, we are proud to contribute to the sustainable growth of companies while supporting the spread of capital to the base and the deepening of our markets.
R&D Infrastructure and Global Value Sourcing
Outlining the deployment matrix of the liquid proceeds and reviewing the brand's long-term orientation within healthcare manufacturing channels, Orzax CEO Yunus Emre Alimoğlu noted:
Since 2004, we have been achieving great things in the health sector with our motto 'Gift to Health'. Today, Orzax has become a brand trusted not only in Turkey but also across many different geographies worldwide. We plan to evaluate the resources obtained from the IPO in three main groups: We will use a portion of the IPO revenues for new investment financing and R&D center developments, a portion in our expansion strategies in global markets, and the remaining part for working capital needs and increasing financial efficiency. With the high capacity and wide product portfolio we possess in our modern production facilities, we have become a brand trusted by pharmacists and consumers today. Before the question of what we will earn, we looked for an answer to the question of 'What will we gift to health'.
